Patents Assigned to Pfizer
  • INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK
    Publication number: 20130267493
    Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Applicant: PFIZER INC.
    Inventors: Samit Bhattacharya, Kimberly Cameron, Matthew Dowling, Dilinie Fernando, David Ebner, Kevin Filipski, Daniel Kung, Esther Lee, Aaron Smith, Meihua Tu
  • Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
    Patent number: 8552207
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 8, 2013
    Assignee: Pfizer Inc.
    Inventors: Joseph F. Krzyzaniak, Jason Albert Leonard
  • Phenanthrenone compounds, compositions and methods
    Patent number: 8552035
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: October 8, 2013
    Assignee: Pfizer Inc.
    Inventor: Paul V. Rucker
  • COLD THERAPY DEVICE
    Publication number: 20130261712
    Abstract: The present invention is directed to a device for absorbing heat from a body. More particularly, the invention pertains to an improved device which utilizes a gel material comprising liquids and solids to absorb, over an extended period of time, heat from a body.
    Type: Application
    Filed: February 13, 2013
    Publication date: October 3, 2013
    Applicant: PFIZER INC
    Inventors: JAMES PATRICK EBEL, MARLE FRANCO, ERIK DOUGLAS LOOMIS
  • Benzofuranyl Derivatives
    Publication number: 20130252973
    Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 26, 2013
    Applicant: Pfizer Inc.
    Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
  • MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
    Publication number: 20130252961
    Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 26, 2013
    Applicant: PFIZER INC.
    Inventors: Simon BAILEY, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
  • Monobactams
    Publication number: 20130252935
    Abstract: The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.
    Type: Application
    Filed: February 27, 2013
    Publication date: September 26, 2013
    Applicant: PFIZER INC.
    Inventors: Matthew F. Brown, Mark J. Mitton-Fry, Seungil Han, Manjinder Lall, Mark Plummer, Hud Lawrence Risley, Veerabahu Shanmugasundaram, Jeremy Starr
  • Pharmaceutical compositions and methods of treating dry eye disorders
    Patent number: 8541426
    Abstract: Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. Jak3 inhibitors useful for treating eye disorders include the compound 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: September 24, 2013
    Assignee: Pfizer Inc.
    Inventors: Channing R. Beals, Elizabeth WoldeMussie, Hovhannes John Gukasyan, Jingwen Ma
  • Sulfonamide derivatives
    Patent number: 8541588
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: September 24, 2013
    Assignees: Pfizer Limited, Icagen, Inc.
    Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
  • NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF
    Publication number: 20130243807
    Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 19, 2013
    Applicant: PFIZER INC.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen
  • System and method for modification of a device and a device suitable for modification
    Patent number: 8535274
    Abstract: The injection device comprises a housing designed or suitable for manual gripping, a container for a preparation attached/enclosed in the housing, an outlet for the preparation exposed with respect to the housing and a mechanism arranged for moving the preparation at least from the container through the outlet. The system comprises a set of at least two elements having different properties in at least one respect. The elements are designed for mechanical attachment to one and the same area part of the housing, one at the time. The method includes the steps of providing at least two elements having different properties in at least one respect, the elements being designed for mechanical attachment to one and the same area part of the housing, one at the time, selecting one element from the set, and attaching mechanically the selected element to said area part of the housing.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: September 17, 2013
    Assignee: Pfizer Health AB
    Inventors: Birger Hjertman, Hans Himbert, Bohdan Pavlu, Kerstin Genetay
  • Fused pyridine compounds as casein kinase inhibitors
    Patent number: 8536164
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, A, R4, n, and R7 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 17, 2013
    Assignee: Pfizer Inc.
    Inventors: Todd W. Butler, Ramalakshmi Y. Chandrasekaran, Scot R. Mente, Chakrapani Subramanyam, Travis T. Wager
  • Device for dispensing a plurality of unitary doses of dry powder, and inhaler comprising such device
    Patent number: 8528549
    Abstract: A device for dispensing a plurality of unitary doses of dry powder includes: first and second supports, an indexing mechanism adapted to move the first and second supports, the indexing mechanism and the supports being configured so that in a first dispensing state of the device, the first and second supports are respectively in engagement with and disengaged from the indexing mechanism, in a second dispensing state of the device, the second and first supports are respectively in engagement with and disengaged from the indexing mechanism, and a changeover mechanism for causing the device to pass from the first dispensing state to the second dispensing state, to lock the second support while the device is in the first dispensing state, and to lock the first support while the device is in the second dispensing state.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 10, 2013
    Assignee: Pfizer Limited
    Inventors: Louise Annabel Bunch, Petra Jane Harris
  • Pyrrolopyrazoles, potent kinase inhibitors
    Patent number: 8530652
    Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 10, 2013
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Junhu Zhang, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
  • DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
    Publication number: 20130225487
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Application
    Filed: March 12, 2013
    Publication date: August 29, 2013
    Applicant: Pfizer Inc.
    Inventor: Pfizer Inc.
  • 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
    Patent number: 8518952
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: August 27, 2013
    Assignee: Pfizer Inc.
    Inventors: John Frederick Braganza, Michael Raymond Collins, John Charles Kath, Sacha Ninkovic, Hui Li, Daniel Tyler Richter
  • Compounds as casein kinase inhibitors
    Patent number: 8518944
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: August 27, 2013
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Travis T. Wager
  • Methods of using engineered ketoreductase polypeptides for the stereoselective reduction of acetophenones
    Patent number: 8512973
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: August 20, 2013
    Assignees: Codexis, Inc., Pfizer, Inc.
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
  • PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
    Publication number: 20130210800
    Abstract: The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R1, R2, R3, R4, R5, R5b, R6, R7, R8, R9, R10, R11, R20, R21, R22 and R23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 15, 2013
    Applicant: PFIZER INC.
    Inventors: Sajiv Krishnan Nair, Simon Paul Planken
  • CANCER TREATMENT
    Publication number: 20130209479
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject's response to a cancer treatment.
    Type: Application
    Filed: April 10, 2013
    Publication date: August 15, 2013
    Applicant: PFIZER, INC.
    Inventor: PFIZER INC.